Gilberto Cruz Arteaga
Quick facts
Phase 3 pipeline
- Azithromycin / Ivermectin / Ribaroxaban / Paracetamol · Multi-indication (Infectious Disease / Parasitology / Cardiovascular / Pain Management)
This is a fixed-dose combination of four active ingredients with distinct mechanisms: azithromycin inhibits bacterial protein synthesis, ivermectin paralyzes parasites, rivaroxaban inhibits factor Xa in the coagulation cascade, and paracetamol reduces pain and fever through central nervous system effects. - Azithromycin / Ribaroxaban / Paracetamol · Infectious Disease / Cardiovascular / Pain Management
This is a fixed-dose combination of three drugs: azithromycin (a macrolide antibiotic), rivaroxaban (an anticoagulant), and paracetamol (an analgesic/antipyretic) that work through distinct mechanisms.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Gilberto Cruz Arteaga
What is Gilberto Cruz Arteaga's pipeline?
Gilberto Cruz Arteaga has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Azithromycin / Ivermectin / Ribaroxaban / Paracetamol, Azithromycin / Ribaroxaban / Paracetamol.
Related
- Sector hub: All tracked pharma companies